QCLS Q/C TECHNOLOGIES, INC.
$1.89 -1.57%
Updated
Healthcare · In Vitro & In Vivo Diagnostic Substances
Q/C TECHNOLOGIES, INC. (QCLS) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $15 million. Shares last traded at $1.89, 79.9% below their 52-week high. Revenue declined 5.3% year over year.
Market Cap
$15M
Shares Out
8.2M
EPS (TTM)
$-203.41
P/E Ratio
—
P/S Ratio
9.79
P/B Ratio
0.96
Dividend / Share
—
Dividend Yield
—
52-Week High
$9.37
52-Week Low
$1.86
Volume
8,243
Avg Vol (3m)
5,643.905
Performance
1W
-20.96%
1M
-36.32%
3M
-49.87%
6M
-45.91%
YTD
-55.12%
1Y
—
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
18.35
SMA (50)
$3.03
SMA (200)
$3.83
Price vs SMA50
-37.70%
Price vs SMA200
-50.82%
ATR (14)
$0.15
Financials
Revenue
$2M
Net Income
$-17M
Gross Margin
30.4%
Operating Margin
-897.2%
Net Margin
—
Return on Equity
-102.9%
Return on Assets
-72.4%
Current Ratio
3.29
Debt / Equity
0.24
Revenue Growth (YoY)
-5.3%
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-0.99 | 2026-08-12 |
| Q1 2026 | $-0.19 | 2026-05-15 |
| FY 2025 | $-8.66 | 2026-04-15 |
| Q3 2025 | $-14.77 | 2025-11-19 |
| Q2 2026 | $-187.46 | 2026-08-12 |
| Q1 2026 | $-0.36 | 2026-05-15 |
In Vitro & In Vivo Diagnostic Substances peers
QCLS vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap. Updated
P/S vs peers
9.79 / 4.24 med
+131% premium
1–14 of 14
| IDXX | Idexx Laboratories | $41.7B | 36.58 | 9.16 | 25.0% | -1.81% |
| LNTH | Lantheus Holdings, Inc. | $6.6B | 23.94 | 4.24 | 17.7% | +0.17% |
| CLDX | Celldex Therapeutics, Inc. | $3.1B | -10.28 | 2000.34 | — | -0.32% |
| NEOG | Neogen Corp | $2.5B | -322.00 | 2.92 | -0.9% | -1.36% |
| NTLA | Intellia Therapeutics, Inc. | $1.8B | -4.44 | — | — | -0.63% |
| QDEL | Quidelortho Corp | $955M | -0.91 | 0.36 | -39.2% | -0.11% |
| ACHV | Achieve Life Sciences, Inc. | $855M | -7.49 | — | — | -2.18% |
| TKNO | Alpha Teknova, Inc. | $388M | -23.12 | 8.87 | -38.4% | -2.83% |
| MYGN | Myriad Genetics Inc | $309M | -2.74 | 0.38 | -14.0% | -0.31% |
| IMDX | Insight Molecular Diagnostics Inc. | $135M | -2.74 | 33.41 | — | +2.99% |
| ICCC | IMMUCELL CORP /DE/ | $90M | 114.19 | 2.93 | 2.6% | -0.35% |
| QCLS | Q/C TECHNOLOGIES, INC. | $15M | -0.93 | 9.79 | — | -1.57% |
| BMRA | BIOMERICA INC | $10M | -2.73 | 2.31 | -84.8% | +2.51% |
| CDIO | Cardio Diagnostics Holdings, Inc. | $5M | -0.84 | 374.80 | — | -1.08% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.